Sanofi SNY reported third-quarter 2024 adjusted earnings of $1.57 per American depositary share, which beat the Zacks ...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...

Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer ...

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for ...

French drugmaker Sanofi's announcement that it will sell a controlling stake in its consumer health division to a U.S.

French pharmaceutical company Sanofi confirmed on Monday its plans to sell a controlling stake in its consumer health ...

Paris: French drugmaker Sanofi's Monday confirmation that it plans to sell a controlling stake in its over-the-counter unit ...

India’s powerful copycat pharmaceutical industry is set to roll out generic weight loss drugs in the U.K. within weeks ...

Analysts at Zacks Research decreased their Q4 2025 earnings estimates for Sanofi in a research note issued on Tuesday, ...

French drugmaker Sanofi's confirmation that it will sell a controlling stake in its consumer health unit to a US investment ...

Paris, October 11, 2024. Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business.

It covers "keeping up a minimum production volume for Opella's sensitive products in France ... made by a different manufacturer. Sanofi, among the world's top 12 healthcare companies, says ...